SLRN News
Archived Headlines
- US IPO Weekly Recap: Kenvue and ACELYRIN fire up the IPO market, raising a combined $4.3 billion 05/05/23
- Immunology biotech ACELYRIN prices further upsized IPO at $18 high end 05/05/23
- Renaissance Capital's April IPO Market Update 05/03/23
- Inflammatory disease biotech ACELYRIN ups share offering by 29% ahead of $451 million IPO 05/03/23
- Inflammatory disease biotech ACELYRIN sets terms for $350 million IPO 05/01/23
See more
Updated: Renaissance Capital's 2023 US IPO Market Review
US IPO Market Slowly Rebuilds in 2023 After sinking to historic lows in the prior year, the US IPO market started to rebuild in 2023, laying the groundwork for the next upcycle. 108 IPOs raised a...read more
Biotechs Apogee and Sagimet slated to kick off the July IPO market
Following the Independence Day lull, the July IPO market is set to warm up with two biotechs that plan to raise $75+ million. The pair are expected to price this week. Apogee Therapeutics (APGE) plans to raise $250 million at the $16 midpoint...read more
Updated: Renaissance Capital's 2Q 2023 US IPO Market Review
US IPO Market Gains Momentum in the 2Q In the second quarter of 2023, 23 IPOs raised a combined $6.6 billion. While deal count held steady from the prior-year period, quarterly proceeds were the...read more
Renaissance Capital's May IPO Market Update
Four sizable IPOs raised a combined $4.9 billion in May, the biggest month for proceeds since December 2021. May activity was well below the 10-year average for deal count (19 IPOs) but on par for proceeds ($5.0B), and the month now accounts for two-thirds of...read more